Levonorgestrel/ethinyl estradiol is a combination birth control medicine used to prevent pregnancy in women. Levonorgestrel/ethinyl estradiol contains 2 types of hormones: levonorgestrel (a progestin) ...

Review the side-effects of Ethinyl Estradiol and Levonorgestrel as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the ...

- Data Demonstrate that Efficacy of a Novel Ascending-Dose, Extended-Regimen Oral Contraceptive is Similar to Other Oral Contraceptives - FRAZER, Pa.--(BUSINESS WIRE)-- Teva Women’s Health, Inc., a ...

NORTH WALES, Pa., Sept. 24, 2013 /PRNewswire/ -- Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette™ ...

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...

PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC to ...

Public advisory - Seasonique and Seasonale birth control pills are being recalled due to the possibility of a missing blister card ...

FRAZER, Pa.--(BUSINESS WIRE)--Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) ...

Shares of Glenmark Pharma climbed 1.7 percent intraday Monday on receiving final approval from the USFDA for its extended cycle oral contraceptives. Advisory Alert: It has come to our attention that ...

(MENAFN- GlobeNewsWire - Nasdaq) Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) ...

Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...